Free Trial

Silverback Therapeutics (SBTX) News Today

Silverback Therapeutics logo
$13.55 -0.24 (-1.74%)
(As of 11/20/2024 ET)
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2%
Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 2%
Silverback Therapeutics, Inc. stock logo
Royce & Associates LP Invests $1.98 Million in Silverback Therapeutics, Inc. (NASDAQ:SBTX)
Royce & Associates LP bought a new position in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 303,900 shares of the company's stock, valued
Silverback Therapeutics, Inc. stock logo
SR One Capital Management LP Purchases 1,003,226 Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX)
SR One Capital Management LP lifted its stake in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Free Report) by 33.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,012,903 shares of the comp
Silverback Therapeutics, Inc. stock logo
Levin Capital Strategies L.P. Boosts Stake in Silverback Therapeutics, Inc. (NASDAQ:SBTX)
Levin Capital Strategies L.P. raised its position in Silverback Therapeutics, Inc. (NASDAQ:SBTX - Free Report) by 259.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,351 shares of the company's
Silverback Therapeutics, Inc. stock logo
Vontobel Holding Ltd. Raises Holdings in Silverback Therapeutics, Inc. (NASDAQ:SBTX)
Vontobel Holding Ltd. grew its position in Silverback Therapeutics, Inc. (NASDAQ:SBTX - Free Report) by 16.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 169,732 shares of the company's stock after buying an additional 23,8
Silverback Therapeutics, Inc. stock logo
Citigroup Inc. Boosts Stock Holdings in Silverback Therapeutics, Inc. (NASDAQ:SBTX)
Citigroup Inc. increased its position in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) by 22,630.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,014 shares of the company's stock
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics, Inc. (NASDAQ:SBTX) Shares Sold by K2 Principal Fund L.P.
K2 Principal Fund L.P. cut its stake in Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) by 11.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,872,148 shares of the company's stock after selling 375,385 shares
ARS Pharmaceuticals Inc (SPRY)
Silverback Therapeutics, Inc. stock logo
Ergoteles LLC Has $394,000 Stock Position in Silverback Therapeutics, Inc. (NASDAQ:SBTX)
Ergoteles LLC decreased its stake in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) by 22.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 74,544 shares of the company's stock after selling 21,756 sh
Silverback Therapeutics, Inc. stock logo
Rubric Capital Management LP Has $14.23 Million Stock Position in Silverback Therapeutics, Inc. (NASDAQ:SBTX)
Rubric Capital Management LP lifted its position in Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) by 173.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,695,170 shares of the company's stock after buying
SPRY ARS Pharmaceuticals, Inc.
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics, Inc. (NASDAQ:SBTX) Short Interest Up 83.5% in September
Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 996,600 shares, an increase of 83.5% from the September 15th total of 543,000 shares. Approximately 4.1% of the shares of the company are short sold. Based on an average trading volume of 277,600 shares, the short-interest ratio is currently 3.6 days.
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
SBTX Silverback Therapeutics, Inc.
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics, Inc. (NASDAQ:SBTX) Sees Significant Decrease in Short Interest
Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) was the recipient of a large decrease in short interest in July. As of July 15th, there was short interest totalling 553,900 shares, a decrease of 28.2% from the June 30th total of 771,200 shares. Currently, 2.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 424,300 shares, the days-to-cover ratio is currently 1.3 days.
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics, Inc. (NASDAQ:SBTX) Short Interest Down 32.4% in June
Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) saw a large decline in short interest in June. As of June 30th, there was short interest totalling 771,200 shares, a decline of 32.4% from the June 15th total of 1,140,000 shares. Based on an average daily volume of 418,300 shares, the days-to-cover ratio is presently 1.8 days. Currently, 3.2% of the shares of the company are short sold.
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics, Inc. (NASDAQ:SBTX) Short Interest Down 16.5% in May
Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 1,060,000 shares, a decrease of 16.5% from the May 15th total of 1,270,000 shares. Based on an average daily volume of 407,000 shares, the short-interest ratio is presently 2.6 days. Approximately 5.2% of the company's shares are short sold.
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics (NASDAQ:SBTX) Stock Rating Lowered by Zacks Investment Research
Zacks Investment Research lowered Silverback Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday.
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics, Inc. (NASDAQ:SBTX) Short Interest Up 35.2% in April
Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 1,210,000 shares, an increase of 35.2% from the April 15th total of 895,100 shares. Based on an average daily volume of 387,900 shares, the short-interest ratio is presently 3.1 days. Currently, 5.9% of the shares of the company are sold short.
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics (NASDAQ:SBTX) Price Target Cut to $5.00 by Analysts at Stifel Nicolaus
Stifel Nicolaus reduced their price objective on shares of Silverback Therapeutics from $6.00 to $5.00 in a research note on Friday.
Silverback Therapeutics, Inc. stock logo
Silverback Therapeutics (NASDAQ:SBTX) Upgraded to "Buy" at Zacks Investment Research
Zacks Investment Research raised Silverback Therapeutics from a "hold" rating to a "buy" rating and set a $3.75 price objective for the company in a research note on Wednesday.
Get Silverback Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

SBTX Media Mentions By Week

SBTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SBTX
News Sentiment

0.00

0.47

Average
Medical
News Sentiment

SBTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SBTX Articles
This Week

0

0

SBTX Articles
Average Week

Get Silverback Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:SBTX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners